Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency
Evaluate the safety and feasibility of administering recombinant adenovirus containing the ornithine transcarbamylase gene to adults with partial ornithine transcarbamylase deficiency.
Ornithine Transcarbamylase Deficiency Disease
Genetic: recombinant adenovirus containing the ornithine transcarbamylase gene
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||October 1995|
PROTOCOL OUTLINE: This a dose escalation study to estimate the maximum tolerated dose of recombinant adenovirus encoded with the ornithine transcarbamylase gene.
Patients receive a single dose of virus infused into the liver under fluoroscopic guidance. Groups of 3 patients receive successively higher doses of virus; each cohort is observed for safety for 3 weeks before entry of the next group.
Patients are followed weekly for 1 month, then every 3 months until stable.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004386
|Study Chair:||Mark Batshaw||Children's Research Institute|